FORE Biotherapeutics to Present Promising New Data from Phas

Positive data support the potential of plixorafenib to induce deep and durable benefit for patients with BRAF-mutated (V600+) cancers In the V600+ population benefit was observed in both MAPK-inhibitor

Related Keywords

Chicago , Illinois , United States , American , Gewinn Nur , Deric Sherman , American Society Of Clinical Oncology , Physician At Memorial Sloan Kettering Cancer Center , Memorial Sloan Kettering Cancer Center , University Of Miami Sylvester Comprehensive Cancer Center , Linkedin , Twitter , Clinical Oncology , Annual Meeting , Stacie Shepherd , Chief Medical Officer , Ongoing Phase , Macarena De La Fuente , Associate Professor , Miami Sylvester Comprehensive Cancer , Associate Attending Physician , Memorial Sloan Kettering Cancer , Orphan Drug Designation , Drug Administration , Fast Track Designation , Miami Sylvester Comprehensive Cancer Center , Tumor Biology , Fore , Iotherapeutics , Present , Romising , Data , Rom , Hase , Trial , Valuating , Lixorafenib , Ore8394 , Patients , Ith , Raf , Faltered , Dvanced , Olid , Central , Nervous , System , Rumors , Disco , 023 ,